Extended PET scanning in patients with incurable hepatocellular carcinoma (HCC) treated with sorafenib.
Withdrawn
- Conditions
- hepatocellular carcinomaliver cancer10019815
- Registration Number
- NL-OMON32355
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Withdrawn
- Sex
- Not specified
- Target Recruitment
- 10
Inclusion Criteria
1. Incurable HCC,
2. Treatment with sorafenib is/will be started
3. At least 18 years of age
4. A life expectancy of at least 3 month
5. Signed written informed consent
6. Able to comply with the protocol
7. Tumor response confirmed by CT-scan after 3 month (t=0 is start the sorafenib)
Exclusion Criteria
1. Dementia or altered mental status that would prohibit giving of informed consent
2. Pregnant or lactating women.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>An initial negative PET will change in a positive scan</p><br>
- Secondary Outcome Measures
Name Time Method <p>Relation initial PET negative scan and survival benefit </p><br>